ESTABLISHMENT LABS HOLDINGS INC.
Establishment Labs is a global medical technology company focused on patient safety and aesthetic outcomes, initially in breast aesthetics and reconstruction. Its main product is Motiva Implants, a line of silicone gel-filled breast implants sold to medical device distributors and directly to physicians, hospitals and clinics. The product portfolio also includes the Motiva Flora Tissue Expander, used before placement of a long-term implant, and minimally invasive breast procedures and technologies, including Mia Femtech and Preservé. Implant features include surface and barrier technologies and optional RFID identification. Establishment Labs earns money primarily from Motiva Implant sales. Its products are available in over 100 countries through exclusive distributors and, in the United States, Brazil, Argentina and several European countries, through its direct sales force. It also offers extended warranties for an additional cost. Establishment Labs is headquartered in Alajuela, Costa Rica.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $ESTA in the last 30 days.
See all $ESTA insider activity →Establishment Labs reported 3Q 2026 revenue of $71.99M, up 33.9% YoY, with net loss narrowing to ($10.71M). U.S. sales led growth, while gross margin declined to 69.1% due to restructuring and lower-margin sales.
Establishment Labs reported Q3 2026 revenue of $72.0M, up 33.9% YoY, with a net loss of $10.7M. Adjusted EBITDA was $6.4M, and free cash flow was $5.1M, the first positive quarter. The company raised its 2026 revenue outlook to over $274M. U.S. revenue rose 119.0%, and international revenue increased 9.7%.
ESTABLISHMENT LABS HOLDINGS INC. (ESTA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 PRESS RELEASE Investor/Media Contact: Malavika William mwilliam@establishmentlabs.com Establishment Labs ® Reports Third Quarter 2026 Financial Results Revenue Increases 33.9% to $72.0 Million, Driven by 119% U.S. Growth Achieves First Quarter of Positive Operating a
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning ESTA (ESTABLISHMENT LABS HOLDINGS INC.). Coverage has been balanced: 0 bullish, 2 neutral, and 0 bearish.
Recent ESTA coverage spans earnings, financial news and regulation.
Earnings beat on revenue growth but margin pressure from inventory charges.
The combination of strong top-line growth, first positive free cash flow quarter, and raised full-year revenue outlook is likely to support sentiment and valuation multiples.
Likely positive read-through as higher U.S. growth, improved operating leverage, and raised full-year revenue outlook support sentiment and estimates.
The reaffirmed Buy rating may generate modest buying pressure as investors consider the $117 target versus current price.
The extension secures long‑term material supply, reducing operational risk for ESTA.
AlphAI scores every news story that mentions ESTA with an AI model for sentiment and relevance, and aggregates insider trades from ESTABLISHMENT LABS HOLDINGS INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Establishment Labs reported 3Q 2026 revenue of $71.99M, up 33.9% YoY, with net loss narrowing to ($10.71M). U.S. sales led growth, while gross margin declined to 69.1% due to restructuring and lower-margin sales.
Establishment Labs reported Q3 2026 revenue of $72.0M, up 33.9% YoY, with a net loss of $10.7M. Adjusted EBITDA was $6.4M, and free cash flow was $5.1M, the first positive quarter. The company raised its 2026 revenue outlook to over $274M. U.S. revenue rose 119.0%, and international revenue increased 9.7%.
ESTABLISHMENT LABS HOLDINGS INC. (ESTA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 PRESS RELEASE Investor/Media Contact: Malavika William mwilliam@establishmentlabs.com Establishment Labs ® Reports Third Quarter 2026 Financial Results Revenue Increases 33.9% to $72.0 Million, Driven by 119% U.S. Growth Achieves First Quarter of Positive Operating a
TD Cowen reaffirmed a 'Buy' rating and $117 price target for Establishment Labs (ESTA). The stock is trading at a 9.0% discount to its GF Value™ of $65.35. ESTA has a GF Score™ of 78/100, indicating strong growth and valuation metrics, but weaker financial strength and profitability. 4 gurus hold positions, with 3 adding recently.
Establishment Labs extended its silicone supply agreement with NuSil Technology to 2031, with options for five one-year renewals. The amendment updates terms for manufacturing, pricing, and intellectual property, ensuring supply reliability. According to the company, this supports operational planning.
ESTABLISHMENT LABS HOLDINGS INC. (ESTA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On October 14, 2026, Establishment Labs Holdings Inc. (the “Company”), through its wholly owned subsidiary, Establishment Labs, S.A. (“ELSA”), entered into Amendment No. 3 (“Amendment No. 3”) to the Master Supply Agreement (th
Stifel initiated coverage on Establishment Labs (NASDAQ:ESTA) with a Buy rating and $85 price target, citing expected growth and market share gains. The stock has fallen 8.5% in the past week. The company reported Q2 2026 revenue of $67.5M, beating estimates, and raised its full-year revenue outlook. Analysts expect EBITDA positivity by Q3 2025 and positive free cash flow by H2 2026.
Establishment Labs Holdings Inc (ESTA) shares fell 5.2% to $58.45 on October 13, 2026, continuing a 19.8% year-to-date decline. The stock is undervalued by 10.5% according to GF Value™, with a GF Score™ of 76/100. Insiders sold $36.9M in shares over the past year, while some gurus increased their positions. The company shows strong growth but weak financial strength and profitability.
Establishment Labs Holdings (ESTA) received FDA clearance for 28 additional implant sizes. The stock has declined 25.80% over 90 days but gained 61.41% over one year. Analysts see a fair value of $92.00, while the stock closed at $65.29. The company faces risks related to market concentration and profitability.
Establishment Labs received FDA approval to add 28 sizes to its Motiva breast implants in the U.S. The expanded range will be available before year-end, according to the company.
